Janssen Research and Development, LLC, Raritan, USA.
The University of North Carolina, Chapel Hill, NC, USA.
Lung. 2020 Dec;198(6):917-924. doi: 10.1007/s00408-020-00394-7. Epub 2020 Sep 26.
The Saint George's Respiratory Questionnaire (SGRQ) is a frequently used tool to assess health status in pulmonary disease patients. However, its performance characteristics in sarcoidosis patients are not well characterized.
Data from a clinical trial of 138 symptomatic adults with sarcoidosis were used to examine the performance characteristics of SGRQ. Data were available at both baseline and week 24. Other assessments included FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6-min walk distance (6MWD), and Short Form-36 Physical Component Summary (SF-36 PCS) score.
Baseline SGRQ was 46.8, indicating impaired health status. At baseline, SGRQ total score correlated significantly with % predicted FVC, FEV1, ATS dyspnea score, Borg's CR 10 dyspnea score, 6MWD, and SF-36 PCS (r = - 0.37, - 0.32, 0.57, 0.40, - 0.55, and - 0.80, respectively, p < 0.001). Change from baseline in SGRQ score also statistically significantly correlated with change from baseline in these parameters at week 24: r = - 0.25, - 0.20, 0.30, 0.22, - 0.20, - 0.45, respectively (p < 0.05).
The SGRQ correlated with other outcome measures in sarcoidosis initially and with treatment. Improvement in FVC % predicted correlated with improvement in SGRQ. These data suggest the SGRQ may function as a reliable endpoint in clinical sarcoidosis trials.
圣乔治呼吸问卷(SGRQ)是一种常用于评估肺部疾病患者健康状况的工具。然而,其在结节病患者中的性能特征尚未得到很好的描述。
使用一项针对 138 例有症状结节病成人的临床试验数据来检验 SGRQ 的性能特征。数据在基线和 24 周时均可用。其他评估包括 FVC、FEV1、ATS 呼吸困难评分、Borg 的 CR 10 呼吸困难评分、6 分钟步行距离(6MWD)和健康调查简表 36 项躯体成分摘要(SF-36 PCS)评分。
基线时 SGRQ 得分为 46.8,表明健康状况受损。基线时,SGRQ 总分与预计 FVC%、FEV1、ATS 呼吸困难评分、Borg 的 CR 10 呼吸困难评分、6MWD 和 SF-36 PCS 显著相关(r = -0.37、-0.32、0.57、0.40、-0.55 和 -0.80,p < 0.001)。从基线到 24 周的 SGRQ 评分变化也与这些参数从基线到 24 周的变化呈统计学显著相关:r = -0.25、-0.20、0.30、0.22、-0.20、-0.45,分别(p < 0.05)。
SGRQ 与结节病的其他结局指标在初始和治疗时均相关。FVC%预计值的改善与 SGRQ 的改善相关。这些数据表明 SGRQ 可能作为结节病临床试验中的可靠终点。